Cytokinetics, Incorporated (NASDAQ:CYTK) Weekly Ratings on Jun 29, 2018

June 29, 2018 - By Clyde Turner

Cytokinetics, Incorporated (NASDAQ:CYTK) Corporate Logo
During 2018 Q1 the big money sentiment decreased to 0.88. That’s change of 0.23, from 2017Q4’s 1.11. 19 investors sold all, 37 reduced holdings as Cytokinetics, Incorporated ratio fall. 30 increased stakes while 19 funds amassed stakes. Funds hold 36.39 million shares thus 4.65% less from 2017Q4’s 38.16 million shares.
California State Teachers Retirement Systems reported 64,210 shs or 0% of all its holdings. Zacks Invest Mgmt, Illinois-based fund reported 16,868 shs. Wells Fargo And Mn holds 71,156 shs or 0% of its capital. Wellington Mngmt Group Inc Llp reported 2.02 million shs or 0% of all its holdings. Nelson Van Denburg Campbell Wealth Mgmt Grp Limited Liability Co holds 175 shs. Los Angeles & Equity Research Incorporated holds 0% of its capital in Cytokinetics, Incorporated (NASDAQ:CYTK) for 11,059 shs. Federated Pa holds 483 shs. Prelude Cap Management Limited Liability Corporation holds 43,743 shs or 0.02% of its capital. Tower Rech Capital Ltd Com (Trc) holds 0% in Cytokinetics, Incorporated (NASDAQ:CYTK) or 1,073 shs. 2.36 million are owned by State Street. Moreover, Thrivent Fin For Lutherans has 0% invested in Cytokinetics, Incorporated (NASDAQ:CYTK) for 32,906 shs. State Of Alaska Department Of Revenue reported 16,349 shs stake. Clarivest Asset Management Lc holds 83,974 shs. Morgan Stanley invested in 0% or 141,059 shs. Gp One Trading Lp invested in 35,050 shs.

Cytokinetics, Incorporated registered $147,942 net activity with 0 insider purchases and 5 selling transactions since January 16, 2018. 4,000 shs were sold by Blum Robert I, worth $33,116 on Tuesday, June 5. Another trade for 3,000 shs valued at $26,850 was made by Malik Fady Ibraham on Thursday, June 7.

Cytokinetics, Incorporated (NASDAQ:CYTK) Ratings Coverage

A total of 2 analysts rate Cytokinetics Inc (NASDAQ:CYTK) as follows: 2 “Buy”, 0 “Hold” and 0 “Sell”. Тherefore 100% are bullish. (NASDAQ:CYTK) has 4 ratings reports on Jun 29, 2018 according to StockzIntelligence. On Monday, June 18 the firm earned “Buy” rating by H.C. Wainwright. On Friday, January 19 the stock of Cytokinetics, Incorporated (NASDAQ:CYTK) has “Buy” rating given by H.C. Wainwright. On Wednesday, February 21 the rating was maintained by Morgan Stanley with “Overweight”. The company rating was maintained by H.C. Wainwright on Friday, April 27. Listed here are Cytokinetics, Incorporated (NASDAQ:CYTK) PTs and latest ratings.

18/06/2018 Broker: H.C. Wainwright Rating: Buy New Target: $24.0000 Maintain
27/04/2018 Broker: H.C. Wainwright Rating: Buy New Target: $20.0000 Maintain
21/02/2018 Broker: Morgan Stanley Old Rating: Overweight New Rating: Overweight Old Target: $17 New Target: $18 Maintain
19/01/2018 Broker: H.C. Wainwright Rating: Buy New Target: $20.0 Maintain

CYTK is reaching $8.3 during the last trading session, after increased 1.22%.Currently Cytokinetics, Incorporated is downtrending after 37.37% change in last June 29, 2017. CYTK has 89,205 shares volume. The stock underperformed the S&P500 by 49.94%.

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining.The company has $449.84 million market cap. The firm is developing small molecule drug candidates primarily engineered to increase muscle function and contractility.Currently it has negative earnings. The Company’s lead drug candidate is Tirasemtiv, a fast skeletal troponin activator, which is in Phase III clinical trial in patients with amyotrophic lateral sclerosis.

For more Cytokinetics, Incorporated (NASDAQ:CYTK) news brought out recently go to: Nasdaq.com, Benzinga.com, Streetinsider.com, Nasdaq.com or Nasdaq.com. The titles are as follows: “Cytokinetics Announces Data From Phase 2 Clinical Study of Reldesemtiv in Patients With Spinal Muscular Atrophy …” brought out on June 16, 2018, “60 Biggest Movers From Yesterday” on June 19, 2018, “Cytokinetics (CYTK) Announces Data From Phase 2 Clinical Study of Reldesemtiv in Patients With Spinal Muscular …” with a publish date: June 08, 2018, “Mid-Day Market Update: Verastem Shares Climb On Duvelisib Data; ZIOPHARM Oncology Shares Slide” and the last “Cytokinetics Announces Data From Phase 2 Clinical Study of Reldesemtiv in Patients With Spinal Muscular Atrophy to …” with publication date: June 08, 2018.

Cytokinetics, Incorporated (NASDAQ:CYTK) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: